Wook-Jin Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wook-Jin Park has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Nakagawa
Institute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
1 shared publication Blair Williams
Institute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
1 shared publication- Dapeng Zhang
East China University of Science and Technology
1 shared publication - Drew Weissman
University of Pennsylvania
1 shared publication - Elena N. Atochina-Vasserman
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
1 shared publication Ishana Baboo
Institute for RNA Innovation, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eadv1554
One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development
There have been rapid advances in nucleoside-modified messenger RNA–based vaccines, particularly during the SARS-CoV-2 pandemic, demonstrating a rapid and cost-effective approach for addressing infectious diseases. A major challenge remains in developing a delivery system that protects mRNA from degradation and facilitates its passage through tissue and cellular barriers. Current four-component lipid nanoparticles enable efficient endosomal escape and are a pivotal technology for the delivery of mRNA vaccines. However, challenges such as stability, availability, durability, and adverse effects persist. We have developed a self-assembling one-component ionizable amphiphilic Janus dendrimers (IAJD) delivery system with naturally occurring amino heads, capable of efficiently delivering mRNA to the spleen and lymph nodes. This single-component system simplifies synthesis, reduces development complexity, and enables rapid global distribution of mRNA vaccines during pandemics. As a proof of concept, one-component IAJD97, formulated with mRNA encoding norovirus mRNA capsid protein, demonstrates the potential of IAJDs as efficient delivery platform for mRNA vaccines, advancing their effectiveness and expanding applications to improve public health outcomes.
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eadv1554
Open AccessOne-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development
There have been rapid advances in nucleoside-modified messenger RNA–based vaccines, particularly during the SARS-CoV-2 pandemic, demonstrating a rapid and cost-effective approach for addressing infectious diseases. A major challenge remains in developing a delivery system that protects mRNA from degradation and facilitates its passage through tissue and cellular barriers. Current four-component lipid nanoparticles enable efficient endosomal escape and are a pivotal technology for the delivery of mRNA vaccines. However, challenges such as stability, availability, durability, and adverse effects persist. We have developed a self-assembling one-component ionizable amphiphilic Janus dendrimers (IAJD) delivery system with naturally occurring amino heads, capable of efficiently delivering mRNA to the spleen and lymph nodes. This single-component system simplifies synthesis, reduces development complexity, and enables rapid global distribution of mRNA vaccines during pandemics. As a proof of concept, one-component IAJD97, formulated with mRNA encoding norovirus mRNA capsid protein, demonstrates the potential of IAJDs as efficient delivery platform for mRNA vaccines, advancing their effectiveness and expanding applications to improve public health outcomes.